


# **Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy**

Belinda M. Kumpel, Radka Saldova, Carolien A.M. Koeleman, Jodie L. Abrahams, Agnes Hipgrave Ederveen, Kathryn L. Armour, Natalia I. Olovnikova, Gestur Vidarsson, Rick Kapur, Pauline M. Rudd & Manfred Wuhrer

## Supplementary Table S1

Comparison of glycosylation data (in bold) with findings of earlier studies (in italics)

Reference	Anti-D	% Sialylation	% Galactosylation	% G0	% G1	% G2	% Fucosylation	% Bisected
	<b>Rhophylac</b>		<b>84</b>				<b>80</b>	<b>12</b>
25	<i>Rhophylac</i>		<i>81</i>				<i>82</i>	<i>6</i>
	<b>BRAD3lab-B</b>	<b>29</b>	<b>69</b>	<b>11</b>	<b>35</b>	<b>51</b>		
109	<i>BRAD3lab-B</i>	<i>15</i>	<i>87</i>	<i>2</i>	<i>21</i>	<i>77</i>		
59	<i>BRAD3lab-B</i>			<i>2</i>				
	<b>BRAD3clin-B</b>	<b>32</b>	<b>61</b>	<b>16</b>	<b>39</b>	<b>41</b>		<b>62</b>
109	<i>BRAD3clin-B</i>	<i>26</i>	<i>59</i>	<i>11</i>	<i>59</i>	<i>30</i>		<i>51</i>
	<b>mBRAD3-B</b>	<b>28</b>					<b>79</b>	<b>64</b>
Dalton	<i>mBRAD3-B</i>	<i>20</i>					<i>high</i>	<i>80</i>
	<b>BRAD5lab-B</b>			<b>2</b>				
59	<i>BRAD5lab-B</i>			<i>4</i>				
	<b>BRAD5clin-B</b>	<b>34</b>	<b>64</b>	<b>12</b>	<b>42</b>	<b>43</b>		<b>66</b>
109	<i>BRAD5clin-B</i>	<i>21</i>	<i>64</i>	<i>8</i>	<i>56</i>	<i>36</i>		<i>34</i>
	<b>mBRAD5-B</b>	<b>24</b>					<b>90</b>	<b>42</b>
Dalton	<i>mBRAD5-B</i>	<i>20</i>					<i>high</i>	<i>40</i>
	<b>JAC10-B</b>	<b>46</b>	<b>84</b>	<b>2</b>	<b>24</b>	<b>72</b>		
109	<i>JAC10-B</i>	<i>21</i>	<i>83</i>	<i>5</i>	<i>24</i>	<i>71</i>		
	<b>G12-B</b>	<b>37</b>	<b>84</b>	<b>1</b>	<b>30</b>	<b>69</b>	<b>95</b>	
49	<i>G12-B</i>	<i>33</i>	<i>56</i>				<i>high</i>	
49	<i>G108-B</i>	<i>26</i>					<i>high</i>	
49	<i>Anti-D Ig</i>	<i>30</i>	<i>high</i>	<i>7</i>	<i>23</i>	<i>41</i>	<i>medium</i>	
	<b>rBRAD3-CHO</b>	<b>5</b>	<b>33</b>	<b>49</b>	<b>33</b>	<b>16</b>	<b>74</b>	<b>0</b>
Dalton	<i>rBRAD3-CHO</i>	<i>5</i>	<i>36</i>	<i>45</i>	<i>38</i>	<i>17</i>	<i>high</i>	<i>0</i>
	<b>rBRAD5-CHO</b>	<b>4</b>	<b>26</b>	<b>56</b>	<b>37</b>	<b>7</b>	<b>91</b>	<b>0</b>
Dalton	<i>rBRAD5-CHO</i>	<i>5</i>	<i>31</i>	<i>49</i>	<i>41</i>	<i>10</i>	<i>high</i>	<i>0</i>
82	<i>T125(R297)-CHO</i>		<i>26</i>	<i>56</i>	<i>37</i>	<i>7</i>	<i>81</i>	
	<b>R297-YB2/O</b>		<b>45</b>	<b>29</b>	<b>52</b>	<b>19</b>	<b>34</b>	
82	<i>T125(R297)-YB2/O</i>		<i>41</i>	<i>33</i>	<i>53</i>	<i>14</i>	<i>32</i>	



**Figure S1. NP-HPLC chromatograms of released N-glycans from IVIG and anti-Ds**